PPD has further demonstrated its commitment to the Russian and wider Central and Eastern European markets by opening an office in Novosibirsk, the fourth Russian city in which the US-based contract research organisation (CRO) has established a presence.

The company says it is now one of the largest CROs operating in Central and Eastern Europe, “an important, high-growth market for clinical trials that offers efficient access to patients and a well-developed, centralised healthcare system”. PPD also has Russian offices in Moscow, Smolensk and St Petersburg.

Building on the growth of its Phase II-IV clinical development services in Eastern Europe, the CRO will provide clinical monitoring services in key therapeutic areas from the new location.

“Establishing a presence in Novosibirsk allows us to serve clients more effectively and keep pace with clinical trial growth in this region,” commented Roger Newbery, PPD's vice-president of clinical development for Europe, Middle East and Africa.

The latest expansion will enable PPD “to reach more than five million people” and to increase the number of investigator sites it uses to meet growing client demand, Newbery added.

In February 2009, PPD agreed to acquire AbCRO Inc, an American-owned and -managed CRO operating in Central and Eastern Europe. The deal gave PPD immediate access to established infrastructure and expertise in Romania, Bulgaria, Serbia and Croatia, while bolstering its existing staff and operations in Poland, Russia and Ukraine.

Last May, PPD opened a pharmacovigilance and medical communications centre in the Bulgarian capital, Sofia.